Skip to main content
Grafa
Summit reports HARMONi survival hazard ratio of 0.76
Image for illustrative purposes only. Not a real photo.

Summit reports HARMONi survival hazard ratio of 0.76

Share
  • Summit reported an overall-survival hazard ratio of 0.76 in the updated Phase III HARMONi analysis.
  • Summit shares were up 8.3% at $14.63 in premarket trading following the announcement.
  • The company submitted the updated results to the FDA ahead of its November 14, 2026, regulatory decision target.

Summit Therapeutics (NASDAQ:SMMT) reported a 0.76 overall-survival hazard ratio in its updated global Phase III HARMONi analysis submitted to the FDA.

The ratio improved from 0.79 in April 2025 and 0.78 in September 2025 as follow-up among western patients increased.

The June analysis included 23.2 months of western follow-up, but Summit has not disclosed updated median survival or confidence intervals.

Following the announcement, Summit Therapeutics's share price was up 8.3% at $14.63 in premarket trading.

Summit’s FDA application seeks approval for ivonescimab plus chemotherapy, with a regulatory decision targeted for November 14, 2026.

HARMONi previously showed median survival of 16.8 months versus 14.0 months and a statistically significant progression-free-survival benefit.